NCT05331222

Proof-of-Concept Interventional Study With a Nasal Spray of JT-1 in Patients With Chronic Rhinitis or Chronic Sinusitis

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Jantar GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Proof-of-concept study with a novel nasal spray in chronic rhinitis or chronic sinusitis. The study will involve 25 patients completing the study for a per protocol analysis.

Detailed description

Visit 1 (Day 0): Screening visit. Assessment of outcome measures Visit 2 (Day 7): Enrollment visit after a 1-week wash-out period. Enrolled to the Study are only patients who show a severe enough and stable disease (SNOT score \>20 and change of SNOT score \<15% compared to Visit 1, respectively). Visit 3 (Day 21): Assessment of outcome measures after 2-week treatment phase Visit 4 (Day 49): Follow-up visit

Conditions

• Chronic Rhinitis
• Chronic Sinus Congestion

Interventions

Type	Name	Description
DRUG	JT-1	JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.

Timeline

• Start date: 2022-09-30
• Primary completion: 2023-03-03
• Completion: 2023-03-03
• First posted: 2022-04-15
• Last updated: 2023-03-21

Locations

1 site across 1 country: Switzerland